![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » ImaRx Therapeutics Completes $7 Million Financing
ImaRx Therapeutics Completes $7 Million Financing
March 10, 2005
ImaRx Therapeutics, a biopharmaceutical company developing NanoInvasive therapies for stroke and cancer, has announced the placement of 2.3 million shares of common stock raising gross proceeds of $7 million. The company will use the net proceeds to, among other items, fund the clinical trials of its lead technology, SonoLysis, which incorporates MRX-815 nanobubbles and ultrasound to dissolve blood clots. A Phase I/II clinical trial for the treatment of peripheral arterial occlusions as well as a Phase II trial for stroke is scheduled to begin in second quarter 2005.
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct